5 mg of Semaglutide: What This Dose Actually Means for Weight Loss

Is 5 mg a real semaglutide dose, or is something else going on?

The short answer is that 5 mg does not appear anywhere in the licensed semaglutide schedule for weight management in the UK. It's possible the figure is being confused with tirzepatide (Mounjaro), which does have a 5 mg weekly dose as part of its titration ladder. Tirzepatide and semaglutide are often discussed together, and the numbers can blur, especially if you've been reading content written for a US audience, where different brand names and doses circulate.

Semaglutide injections for weight loss are marketed as Wegovy. The NHS medicines page for semaglutide confirms the standard escalation: you begin at 0.25 mg weekly for the first four weeks, then step up gradually under prescriber direction through 0.5 mg, 1 mg, and 1.7 mg, arriving at the 2.4 mg maintenance dose. In January 2026, the MHRA also approved 7.2 mg as an additional maintenance option, and our page on 7.5 semaglutide explains why searches for that figure often lead people to the newly approved 7.2 mg step. None of these steps passes through 5 mg.

If you have a query specifically about the 1 mg or 1.7 mg stages of the Wegovy schedule, our pages on 1 mg semaglutide and the 1.7 mg dose go into detail on what to expect at those points.

Could the 5 mg figure relate to Rybelsus or the new Wegovy tablet?

It's a reasonable guess, but still no. Rybelsus is an oral semaglutide tablet, made by Novo Nordisk and licensed specifically for type 2 diabetes, not weight management. Its dose steps are 3 mg, 7 mg, and 14 mg. Those three figures look close to the kind of numbers people search for, but Rybelsus is a completely separate product from Wegovy, and it is not prescribed for weight loss.

The oral Wegovy tablet (approved by the MHRA on 11 June 2026 as the first oral GLP-1 weight-loss medicine licensed in the UK) uses a different set of doses again: 1.5 mg, 4 mg, 9 mg, and 25 mg. Again, no 5 mg step. For a fuller picture of how the Wegovy injection and tablet differ, that page covers both in one place. The key practical point is that the Wegovy tablet schedule and the Rybelsus diabetes schedule must never be mixed up, they serve different conditions and the doses do not overlap in a meaningful clinical way.

For context on how the injection steps compare across the schedule, our overview of Wegovy doses lays out the full titration pathway from start to maintenance.

What does this mean if you're trying to work out your own dose?

Dose decisions are not something to navigate from search results. The titration schedule exists because semaglutide's most common side effects (nausea, digestive discomfort, fatigue in the early weeks) are meaningfully reduced when the dose rises slowly and the prescriber can check in at each stage. Starting at 0.25 mg for four weeks is not a low-impact opening act; it's a deliberate approach to tolerability.

The NICE recommendation for Wegovy (TA875) notes that continuing treatment should be reviewed if less than 5% weight loss is achieved after six months at the maintenance dose. That kind of individual assessment (balancing how someone is tolerating the medicine against how it's working for them) is exactly what a prescriber does. A page on the internet cannot do it. If you're on treatment already and wondering whether your dose should change, that conversation belongs with your prescriber, not with a search engine.

Some people also search for specific dose comparisons because they're deciding between semaglutide and tirzepatide. The weight-loss treatment overview at nume is a reasonable starting point, and the 10 mg semaglutide page explains why that particular search leads people to tirzepatide rather than Wegovy.

How does semaglutide for weight loss reach you in practice?

If a prescriber confirms Wegovy is appropriate for you, the pen is dispensed through a GPhC-registered pharmacy and dispatched the same day if you order before midday on a working day. What arrives is a tracked DPD parcel (plain, unbranded packaging) with the Wegovy KwikPen inside. Each pen contains four weekly doses, so there's no multi-pen complexity to manage at the start. Storage is in the fridge, and the patient information leaflet inside the box covers every practical detail: injection sites, what to do if a dose is missed, how to handle the pen.

The legitimate route to any licensed weight-loss medicine in the UK runs through a prescriber and a GPhC-registered pharmacy you can verify on the public register. There is no shortcut around that, and any seller offering semaglutide without a prior clinical assessment is operating outside the law. Our FAQs page covers common questions about the prescription process if you want more detail before starting.

Thinking about whether a GLP-1 medicine is the right move? Speak to our prescribers through a free consultation at nume, a real clinician reads your answers the same day, not software.